期刊文献+

原位移植人肝癌裸鼠模型AFP基因的异常甲基化检测 被引量:1

The aberrant methylation status of AFP gene in orthotopic implanted human primary hepaticcarcinoma in nude mice models
下载PDF
导出
摘要 【目的】研究原位异种移植肝癌模型AFP基因启动子区异常甲基化状态的检出状况,探讨其在肝癌发病机制研究中的应用。【方法】采用甲基化特异性PCR(MSP)和亚硫酸氢盐测序法(BSP),以人成纤维细胞基因组甲基化状态为正常对照,对10例原位移植人肝癌裸鼠模型肝癌组织中AFP基因启动子区甲基化状态进行分析和定位。【结果】10例模型肝癌组织中AFP基因启动子区甲基化状态均发生了不同程度的异常。【结论】原位移植人肝癌模型的肝癌组织中可以检测到AFP基因启动子区的去甲基化变化,MSP和BSP作为简便而有效的技术组合可以应用于基因甲基化状态的鉴定中。 [Objective] To investigate the aberrant methylation status in the promoter region of AFP gene and try to find out it' s application in the research on the hepatocarcinogenesis mechanism. [ Methods] The methylation status of the AFP gene in the liver cancers from 10 orthotopic implanted nude mice models of human hepatocellnlar carcinoma were detected and analyzed by MSP and BSP. The ones of genome from human fibroblasts cells were the controls. [Results] The methylation status from all the mice had changed. [Conclusion ] The methylation status in the promoter region of AFP gene is abnormal. MSP and BSP are the efficient and essential methods.
出处 《武警医学院学报》 CAS 2011年第8期622-624,F0003,共4页 Acta Academiae Medicinae CPAPF
关键词 原位移植 AFP基因 甲基化 肝癌 Orthotopic implantation AFP gene Methylation Hepatoma
  • 相关文献

参考文献2

二级参考文献14

  • 1梁法汤,张子彦,梁法禹.FHIT蛋白在原发性肝癌的表达及意义[J].传染病信息,2005,18(z1):68-69. 被引量:3
  • 2张永彪,褚嘉祐.表观遗传学与人类疾病的研究进展[J].遗传,2005,27(3):466-472. 被引量:49
  • 3Simile MM,Pagnan G,Pastorino F,et al.Chemopreventive N-(4-hyaroxyphenyl)retinamide(fenretinide)targets deregulated NF-kB and Mat1A genes in the early stages of rat liver carcinogenesis[J].Carcinogenesis,2005,26(2):417-427. 被引量:1
  • 4Lelunann U,Wingen LU,Brakensiek K,et al.Epigenetic defects of hepatocellular carcinoma are already found in non-neoplastic liver cells from patients with hereditary haemochromatosis[J].Hum Mol Genet,2007,16(11):1335-1342. 被引量:1
  • 5Calvisi DF,Ladu S,Gorden A,et al.Mechanistic and prognostic signifi-cance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma[J].J Clin Invest,2007,117(9):2713-2722. 被引量:1
  • 6Absood A,Hu B,Bassily N,et al.VIP inhibits human HepG2 cell proliferation in vitro[J].Regul Pept,2008,146(1-3):285-292. 被引量:1
  • 7Futakuchi M,Hirose M,Ogiso T,et al.Establishment of an in vivo highly metastatic rat hepatocellular-carcinoma model[J].Jpn J Cancer Res,1999,90(11):1196-1202. 被引量:1
  • 8Wilkinson DS,Ogden SK,Stratton SA,et al.A direct intersection between p53 and transforming growth factor beta pathways targets chromatin modification and transcription repression of the alpha-fetoprotein gene[J].Mol Cell Biol,2005,25(3):1200-1212. 被引量:1
  • 9Liu J,Benbrahim-Talla L,Qian X,et al.Further Studies on aberrant gene expression associated with arsenic-induced malignant transformation in rat liver TRL1215 cells[J].Toxicol Appl Pharmacol,2006,216(3);4007-4015. 被引量:1
  • 10Nguyen TT,Cho K,Stratton SA,et al.Transcription factor interactions and chromatin modifications associated with p53-mediated,developmental repression of the alpha-fetoprotein gene[J].Mol Cell Biol,2005,25(6):2147-2157. 被引量:1

共引文献5

同被引文献13

  • 1Chen JG, Zhang SW. Liver cancer epidemic in China: past, pres-ent and future. Semin Cancer Biol,2011,21 (1) :59-69. 被引量:1
  • 2Lencioni R, Chen XP, Dagher L, et al. Treatment of intermedi-ate/ advanced hepatocellular carcinoma in the clinic : how can out-comes be improved?. Oncologist,2010,15 Suppl 4:42-52. 被引量:1
  • 3Skinner HD, Hong TS,Krishnan S. Charged-particle therapy forhepatocellular carcinoma. Semin Radiat Oncol,2011,21(4) :278-286. 被引量:1
  • 4Petruzelka L. Targeted biological treatment of solid tumours. VnitrLek,2011,57(9) :740-744. 被引量:1
  • 5Cabibbo G, Craxl A. Epidemiology, risk factors and surveillanceof hepatocellular carcinoma. Eur Rev Med Pharmacol Sci ,2010,14(4):352-355. 被引量:1
  • 6Malaguamera G, Giordano M, Paladina I, et al. Serum markers ofhepatocellular carcinoma. Dig Dis Sci,2010,55( 10) :2744-2755. 被引量:1
  • 7Dalpke AH. Vaccination—new facts from basic research. MMWFortschr Med,2010,152 Suppl 2:42-46. 被引量:1
  • 8O'Neill DW. Dendritic cells and T cells in immunotherapy. JDrugs Dermatol,2010,9(11) :1383-1392. 被引量:1
  • 9Jain KK. Personalized cancer vaccines. Expert Opin Biol Ther,2010,10(12) :1637-1647. 被引量:1
  • 10Shurin MR, Gregory M, Morris JC, et al. Genetically modifieddendritic cells in cancer immunotherapy: a better tomorrow?.Expert Opin Biol Ther,2010,10( 11) : 1539-1553. 被引量:1

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部